Cefotetan in the treatment of obstetric and gynecologic infections

Alfred N. Poindexter, Richard L Sweet, Marcella Ritter

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The efficacy, tolerance, and safety of cefotetan-a new 7-α-methoxy cephalosporin-was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.

Original languageEnglish (US)
Pages (from-to)946-950
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume154
Issue number4
DOIs
StatePublished - 1986

Fingerprint

Cefotetan
Obstetrics
Infection
Moxalactam
Cefoxitin
Cost Control
Diagnosis-Related Groups
Cephalosporins
Therapeutics
Pharmaceutical Preparations
Cost-Benefit Analysis
Appointments and Schedules
Safety

Keywords

  • antibiotics
  • Cefotetan
  • endometritis
  • pelvic inflammatory disease

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Cefotetan in the treatment of obstetric and gynecologic infections. / Poindexter, Alfred N.; Sweet, Richard L; Ritter, Marcella.

In: American Journal of Obstetrics and Gynecology, Vol. 154, No. 4, 1986, p. 946-950.

Research output: Contribution to journalArticle

Poindexter, Alfred N. ; Sweet, Richard L ; Ritter, Marcella. / Cefotetan in the treatment of obstetric and gynecologic infections. In: American Journal of Obstetrics and Gynecology. 1986 ; Vol. 154, No. 4. pp. 946-950.
@article{f4b58fd13509458aa319b6d70b6e631a,
title = "Cefotetan in the treatment of obstetric and gynecologic infections",
abstract = "The efficacy, tolerance, and safety of cefotetan-a new 7-α-methoxy cephalosporin-was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99{\%} satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.",
keywords = "antibiotics, Cefotetan, endometritis, pelvic inflammatory disease",
author = "Poindexter, {Alfred N.} and Sweet, {Richard L} and Marcella Ritter",
year = "1986",
doi = "10.1016/0002-9378(86)90495-3",
language = "English (US)",
volume = "154",
pages = "946--950",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Cefotetan in the treatment of obstetric and gynecologic infections

AU - Poindexter, Alfred N.

AU - Sweet, Richard L

AU - Ritter, Marcella

PY - 1986

Y1 - 1986

N2 - The efficacy, tolerance, and safety of cefotetan-a new 7-α-methoxy cephalosporin-was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.

AB - The efficacy, tolerance, and safety of cefotetan-a new 7-α-methoxy cephalosporin-was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.

KW - antibiotics

KW - Cefotetan

KW - endometritis

KW - pelvic inflammatory disease

UR - http://www.scopus.com/inward/record.url?scp=0022632316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022632316&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(86)90495-3

DO - 10.1016/0002-9378(86)90495-3

M3 - Article

C2 - 3515949

AN - SCOPUS:0022632316

VL - 154

SP - 946

EP - 950

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -